Mark Elliott Boulding Ptc Therapeutics, Inc. (PTCT) insider trading activity

Mark Elliott Boulding is EXEC. VP AND CLO of PTC THERAPEUTICS, INC.. Currently has a direct ownership of 103,901 shares of PTCT, which is worth approximately $5.18 Million. The most recent transaction as insider was on Jan 31, 2023, when has been sold 812 shares (Common Stock) at a price of $45.63 per share, resulting in proceeds of $37,051. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 104K

0% 3M change

12.46% 12M change

Total Value Held $5.18 Million

Mark Elliott Boulding Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 31 2023	SELL Open market or private sale	$37,051 $45.63 p/Share	812 Reduced 1.07%	75,378 Common Stock
Jan 11 2023	SELL Open market or private sale	$21,958 $44.36 p/Share	495 Reduced 0.65%	76,190 Common Stock
Jan 10 2023	SELL Open market or private sale	$25,328 $42.93 p/Share	590 Reduced 0.76%	76,685 Common Stock
Jan 09 2023	SELL Open market or private sale	$34,786 $41.66 p/Share	835 Reduced 1.07%	77,275 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	17,000 Added 17.87%	78,110 Common Stock
Oct 18 2022	SELL Open market or private sale	$16,520 $55.25 p/Share	299 Reduced 0.49%	61,110 Common Stock
Oct 18 2022	BUY Exercise of conversion of derivative security	$9,227 $30.86 p/Share	299 Added 0.48%	61,399 Common Stock
Oct 17 2022	SELL Open market or private sale	$363,110 $55.0 p/Share	6,602 Reduced 9.75%	61,110 Common Stock
Oct 17 2022	BUY Exercise of conversion of derivative security	$203,738 $30.86 p/Share	6,602 Added 8.91%	67,512 Common Stock
Sep 20 2022	SELL Open market or private sale	$64,680 $55.0 p/Share	1,176 Reduced 1.89%	61,110 Common Stock
Sep 20 2022	BUY Exercise of conversion of derivative security	$36,291 $30.86 p/Share	1,176 Added 1.88%	61,410 Common Stock
Apr 13 2022	SELL Open market or private sale	$102,807 $45.17 p/Share	2,276 Reduced 3.59%	61,110 Common Stock
Apr 13 2022	BUY Exercise of conversion of derivative security	$25,559 $11.23 p/Share	2,276 Added 3.47%	63,386 Common Stock
Apr 05 2022	SELL Open market or private sale	$225 $45.0 p/Share	5 Reduced 0.01%	61,110 Common Stock
Apr 05 2022	BUY Exercise of conversion of derivative security	$56 $11.23 p/Share	5 Added 0.01%	61,115 Common Stock
Feb 10 2022	SELL Open market or private sale	$807,613 $45.03 p/Share	17,935 Reduced 22.69%	61,110 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	$262,210 $14.62 p/Share	17,935 Added 18.94%	76,763 Common Stock
Feb 01 2022	SELL Open market or private sale	$31,160 $40.0 p/Share	779 Reduced 1.26%	61,110 Common Stock
Jan 07 2022	SELL Open market or private sale	$34,090 $38.52 p/Share	885 Reduced 1.83%	47,489 Common Stock
Jan 07 2022	BUY Grant, award, or other acquisition	-	14,400 Added 18.88%	61,889 Common Stock
Sep 02 2021	SELL Open market or private sale	$151,369 $45.01 p/Share	3,363 Reduced 6.5%	48,374 Common Stock
Sep 02 2021	BUY Exercise of conversion of derivative security	$60,568 $18.01 p/Share	3,363 Added 6.1%	51,737 Common Stock
Jul 09 2021	SELL Open market or private sale	$64,305 $45.0 p/Share	1,429 Reduced 2.87%	48,374 Common Stock
Jul 09 2021	BUY Exercise of conversion of derivative security	$25,736 $18.01 p/Share	1,429 Added 2.86%	48,618 Common Stock
Jul 08 2021	SELL Open market or private sale	$353,020 $45.23 p/Share	7,805 Reduced 13.89%	48,374 Common Stock

MEB

Mark Elliott Boulding

EXEC. VP AND CLO

South Plainfield, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTCT shares.

Notify only if

Value

Insider Trading

Get notified when an Ptc Therapeutics, Inc. insider buys or sells PTCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to PTC THERAPEUTICS, INC.

Track Activities on PTCT

Account